- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07687459
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.
The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).
In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Qinhan Chen
- Número de teléfono: +86 021-50831718
- Correo electrónico: Insilico-Clinicaltrial@insilico.ai
Ubicaciones de estudio
-
-
Anhui
-
Hefei, Anhui, Porcelana
- Aún no reclutando
- Anhui Provincial Hospital
-
Hefei, Anhui, Porcelana
- Aún no reclutando
- Anhui Chest Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Porcelana
- Reclutamiento
- Peking Union Medical College Hospital
-
Beijing, Beijing Municipality, Porcelana
- Reclutamiento
- Beijing Friendship hospital, Capital Medical University
-
Beijing, Beijing Municipality, Porcelana
- Aún no reclutando
- Beijing Chaoyang Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, Porcelana
- Aún no reclutando
- Fuzhou University Affiliated Provincial Hospital
-
Xiamen, Fujian, Porcelana
- Reclutamiento
- The Second Affiliated Hospital of Xiamen Medical College
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana
- Reclutamiento
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Guangdong, Porcelana
- Aún no reclutando
- Nanfang Hospital, Southern Medical University
-
-
Guangxi
-
Nanning, Guangxi, Porcelana
- Aún no reclutando
- The First Affiliated Hospital of Guangxi Medical University
-
-
Hainan
-
Haikou, Hainan, Porcelana
- Reclutamiento
- Hainan General Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, Porcelana
- Aún no reclutando
- The Second Hospital of Hebei Medical University
-
Shijiazhuang, Hebei, Porcelana
- Aún no reclutando
- Hebei Medical University Third Hospital
-
-
Henan
-
Anyang, Henan, Porcelana
- Reclutamiento
- The People's Hospital of Anyang City
-
Nanyang, Henan, Porcelana
- Reclutamiento
- Nanyang First People's Hospital
-
Zhengzhou, Henan, Porcelana
- Aún no reclutando
- Henan Provincial People's Hospital
-
Zhengzhou, Henan, Porcelana
- Aún no reclutando
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, Porcelana
- Aún no reclutando
- Renmin Hospital of Wuhan University
-
Wuhan, Hubei, Porcelana
- Aún no reclutando
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Yichang, Hubei, Porcelana
- Aún no reclutando
- Yichang Central People's Hospital
-
-
Hunan
-
Changsha, Hunan, Porcelana
- Aún no reclutando
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, Porcelana
- Aún no reclutando
- The Xiangya Hospital of Central South University
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, Porcelana
- Aún no reclutando
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana
- Reclutamiento
- Nanjing Drum Tower Hospital
-
Xuzhou, Jiangsu, Porcelana
- Aún no reclutando
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, Porcelana
- Aún no reclutando
- Jiangxi Provincial People' Hospital
-
-
Jilin
-
Changchun, Jilin, Porcelana
- Aún no reclutando
- The Second Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, Porcelana
- Aún no reclutando
- Shengjing Hospital of China Medical University
-
-
Shaanxi
-
Xi'an, Shaanxi, Porcelana
- Reclutamiento
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Xi'an, Shaanxi, Porcelana
- Reclutamiento
- The First Affiliated Hospital of Xi'an Medical College
-
-
Shandong
-
Jinan, Shandong, Porcelana
- Aún no reclutando
- Qilu Hospital of Shandong University
-
Jinan, Shandong, Porcelana
- Aún no reclutando
- Introduction of the First Affiliated Hospital of Shandong First Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana
- Reclutamiento
- Shanghai Pulmonary Hospital Affiliated to Tongji University
-
-
Shanxi
-
Taiyuan, Shanxi, Porcelana
- Aún no reclutando
- Shanxi Bethune Hospital
-
Yuncheng, Shanxi, Porcelana
- Aún no reclutando
- Yuncheng Central Hospital
-
-
Sichuan
-
Chengdu, Sichuan, Porcelana
- Aún no reclutando
- West China Hospital, Sichuan University
-
Chengdu, Sichuan, Porcelana
- Aún no reclutando
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Porcelana
- Aún no reclutando
- Tianjin Medical University General Hospital
-
Tianjin, Tianjin Municipality, Porcelana
- Aún no reclutando
- Tianjin Chest Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, Porcelana
- Aún no reclutando
- The First Affiliated Hospital of Xinjiang Medical University
-
-
Yunnan
-
Kunming, Yunnan, Porcelana
- Aún no reclutando
- The First People Hospital of Yunnan Province
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana
- Aún no reclutando
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, Porcelana
- Reclutamiento
- Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
-
Jiaxing, Zhejiang, Porcelana
- Aún no reclutando
- The First Hospital of Jiaxing
-
Ningbo, Zhejiang, Porcelana
- Aún no reclutando
- Ningbo Medical Center Lihuili Hospital
-
Ningbo, Zhejiang, Porcelana
- Aún no reclutando
- The First Affiliated Hospital of Ningbo University
-
Wenzhou, Zhejiang, Porcelana
- Aún no reclutando
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
- Patients aged ≥40 years at time of signing the ICF.
- Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
- UIP or probable UIP with fibrosis extent >10% at HRCT.
Meet all the following criteria during the screening period:
- FVC ≥45% predicted of normal
- FEV1/FVC ≥0.7
- DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
Background antifibrotic therapies are allowed, patients may be either:
- on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
- not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
- Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
- Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.
Exclusion criteria:
- Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
- Previous participation in a clinical study with rentosertib (active or placebo).
- Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
- Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
- Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
- Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
- Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
- Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
- Patients with Gilbert's disease
- Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
- Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
- Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
- Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
- Patient with a history of lung volume reduction surgery or lung transplant.
- Current smoker and/or cotinine (smoking) test positive.
- History of drug abuse, drug use, or alcohol abuse within the past 3 months.
- Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
- Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
- Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
- Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study
- Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
- Medications associated with substantial risk for prolongation of corrected QT interval.
- Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
- Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
- Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
- Any condition that would interfere with the interpretation of study assessments or impair study participation.
- Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
|
Dosage form: Tablets; Frequency of administration: Orally QD.
Other Names: Rentosertib
|
|
Comparador de placebos: Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
|
Forma farmacéutica: Tableta; Frecuencia de administración: Por vía oral una vez al día.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
Periodo de tiempo: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
time to first occurrence of any disease progression
Periodo de tiempo: up to 52 weeks
|
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
|
up to 52 weeks
|
|
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
Periodo de tiempo: week 52
|
week 52
|
|
|
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
Periodo de tiempo: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
Periodo de tiempo: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
Periodo de tiempo: Weeks 0, 52
|
Weeks 0, 52
|
Otras medidas de resultado
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
Periodo de tiempo: up to 56 weeks
|
up to 56 weeks
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
Periodo de tiempo: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
Periodo de tiempo: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
Periodo de tiempo: weeks 0, 12 ,26, and 52
|
weeks 0, 12 ,26, and 52
|
|
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
Periodo de tiempo: weeks 0, 52
|
weeks 0, 52
|
|
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
Periodo de tiempo: weeks 0, 52
|
weeks 0, 52
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- INS018-055-301
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .